[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567826":3},{"organization":4,"armGroups":7,"interventions":58,"overallOfficials":68,"centralContacts":64,"locations":72,"responsibleParty":96,"collaborators":64,"id":98,"slug":99,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":64,"eligibilityCriteria":104,"healthyVolunteers":105,"sex":106,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":64,"studyType":112,"phases":113,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":119,"whyStopped":64,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},{"fullName":5,"class":6},"AbbVie","INDUSTRY",[8,15,19,23,27,30,34,38,42,46,50,54],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: Group 1","EXPERIMENTAL","Participants will receive a single dose of either ABBV-722 Dose A or placebo.",[13,14],"Drug: ABBV-722","Drug: Placebo",{"label":16,"type":10,"description":17,"interventionNames":18},"Part 1: Group 2","Participants will receive a single dose of either ABBV-722 Dose B or placebo.",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Part 1: Group 3","Participants will receive a single dose of either ABBV-722 Dose C or placebo.",[13,14],{"label":24,"type":10,"description":25,"interventionNames":26},"Part 1: Group 4","Participants will receive a single dose of either ABBV-722 Dose TBD or placebo.",[13,14],{"label":28,"type":10,"description":25,"interventionNames":29},"Part 1: Group 5",[13,14],{"label":31,"type":10,"description":32,"interventionNames":33},"Part 2: Group 6","Participants who are Han Chinese will receive a single dose of ABBV-722 Dose D.",[13],{"label":35,"type":10,"description":36,"interventionNames":37},"Part 2: Group 7","Participants who are Japanese will receive a single dose of ABBV-722 Dose D.",[13],{"label":39,"type":10,"description":40,"interventionNames":41},"Part 3: Group 8","Participants will receive either ABBV-722 Dose E or placebo for 14 days.",[13,14],{"label":43,"type":10,"description":44,"interventionNames":45},"Part 3: Group 9","Participants will receive either ABBV-722 Dose F or placebo for 14 days.",[13,14],{"label":47,"type":10,"description":48,"interventionNames":49},"Part 3: Group 10","Participants will receive either ABBV-722 Dose A or placebo for 14 days.",[13,14],{"label":51,"type":10,"description":52,"interventionNames":53},"Part 3: Group 11","Participants will receive either ABBV-722 Dose G or placebo for 14 days.",[13,14],{"label":55,"type":10,"description":56,"interventionNames":57},"Part 3: Group 12","Participants will receive either ABBV-722 Dose TBD or placebo for 14 days.",[13,14],[59,65],{"type":60,"name":61,"description":62,"armGroupLabels":63,"otherNames":64},"DRUG","ABBV-722","Oral Capsule",[9,16,20,24,28,31,35,47,51,55,39,43],null,{"type":60,"name":66,"description":62,"armGroupLabels":67,"otherNames":64},"Placebo",[9,16,20,24,28,47,51,55,39,43],[69],{"name":70,"affiliation":5,"role":71},"ABBVIE INC.","STUDY_DIRECTOR",[73,86],{"facility":74,"status":64,"city":75,"state":76,"zip":77,"country":78,"countryCode":79,"cosmosGeoPoint":80,"geoPoint":85,"contacts":64},"Altasciences Clinical Los Angeles \u002FID# 280183","Cypress","California","90630","United States","US",{"type":81,"coordinates":82},"Point",[83,84],-118.03729,33.81696,{"lat":84,"lon":83},{"facility":87,"status":64,"city":88,"state":89,"zip":90,"country":78,"countryCode":79,"cosmosGeoPoint":91,"geoPoint":95,"contacts":64},"Acpru \u002FId# 270279","Grayslake","Illinois","60030",{"type":81,"coordinates":92},[93,94],-88.04175,42.34447,{"lat":94,"lon":93},{"type":97,"investigatorFullName":64,"investigatorTitle":64,"investigatorAffiliation":64,"oldNameTitle":64,"oldOrganization":64},"SPONSOR","100567826","phase-1-a-study-to-assess-how-the-drug-moves-through-the-body-adverse-events-and-tolerability-of-oral-abbv-722-capsules-of-single-and-multiple-ascending-doses-in-adult-participants-and-single-doses-in-adult-asian-participants-100567826",false,"NCT06673238","A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants","A First-In-Human Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-722 Following Single and Multiple Ascending Doses in Healthy Adult Subjects and Single Doses in Healthy Adult Asian Subjects","Inclusion Criteria:\n\n* Laboratory values meet the criteria specified in the protocol.\n* A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG).\n* Part 2 only: Healthy Han Chinese and Japanese individuals between 18 and 65 years of age, inclusive at the time of Screening.\n\n  * Participant must be first- or second-generation Han Chinese of full Chinese parentage (both parents of Han Chinese descent), residing outside of China. Participants must be in general good health and maintain a typical Chinese lifestyle, including consuming a typical Chinese diet.\n  * First-generation participants will have been born in China to two parents and four grandparents, who were also born in China, and are of full Chinese descent.\n  * Second-generation participants born outside of China must have two parents and four grandparents born in China and are of full Chinese descent. OR\n  * Participant must be first- or second-generation Japanese of full Japanese parentage (both parents of Japanese descent), residing outside of Japan. Participants must be in general good health and maintain a typical Japanese lifestyle, including consuming a typical Japanese diet.\n  * First-generation participants will have been born in Japan to two parents and four grandparents, who were also born in Japan, and are of full Japanese descent.\n  * Second-generation participants born outside of Japan must have two parents and four grandparents born in Japan and are of full Japanese descent.\n\nExclusion Criteria:\n\n* History of any clinically significant illness\u002Finfection\u002Fmajor febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study drug.\n* Consumption of alcohol, grapefruit products, Seville oranges, starfruit products or quinine\u002Ftonic water within the 72-hour period prior to study drug administration.\n* Use of tobacco or nicotine-containing products within 180 days prior to the first dose of study drug.",true,"ALL","18 Years","65 Years",{"count":110,"type":111},95,"ACTUAL","INTERVENTIONAL",[114],"PHASE1","This is a Phase 1, first-in-human study to investigate safety, tolerability, and pharmacokinetics of ABBV-722 after oral dosing in healthy adult participants.",[117],"Healthy Volunteer",[117,61],"COMPLETED","2026-07-24",{"date":122,"type":111},"2026-07-27",{"date":124,"type":111},"2024-10-29",{"date":126,"type":111},"2026-06-25",{"name":5,"class":6},2]